Skip to main content

Advertisement

SpringerLink
Log in

Effect of etanercept and entecavil in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature

  • Case Report
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

In this report, we describe a case of a 48-year-old Japanese woman who is a hepatitis B (HB) carrier with rheumatoid arthritis (RA). She had the following antibody profile: HBs Ag(+), HBs Ab(−), HBe Ag(−), HBe Ab (+), HBc Ab(−) and undetectable HBV-DNA level. She was treated with auranofin, salazosulfapyridine, and bucillamine. Finally, she was treated with d-penicillamine, but her disease activity remained elevated. Prophylactic treatment of entecavir 0.5 mg daily was started in March 2008 and all disease-modifying anti-rheumatic drugs were stopped. After 2 weeks, etanercept monotherapy was started at 25 mg subcutaneously once a week. Significant improvement in clinical parameters of disease activity and well being was observed. Serum alanine aminotransferase (ALT), serum aspartate aminotransferase (AST), and HB virus viral load did not change significantly. Serum ALT, AST, and HB virus viral load were followed-up at every 3-month intervals, from initiation of therapy up to 24 months after the start of treatment with etanercept. We have also summarized the course of nine RA patients who received etanercept and were HB carriers or had chronic HB according to our literature search. Based on the results of our study, treatment of these patients with etanercept co-administered with lamivudine or entecavir appears to be safe.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, Spitz PW, Haga M, Kleinheksel SM, Cathey MA (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37(4):481–494

    Article  PubMed  CAS  Google Scholar 

  2. Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF (1986) Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 29(6):706–714

    Article  PubMed  CAS  Google Scholar 

  3. Prior P, Symmons DP, Scott DL, Brown R, Hawkins CF (1984) Cause of death in rheumatoid arthritis. Br J Rheumatol 23(2):92–99

    Article  PubMed  CAS  Google Scholar 

  4. Boers M, COBRA Study Group (2001) Combinatie therapie Bij Reumatoide Artritis. Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy. Arthritis Rheum 44(11):2703–2704

    Article  PubMed  CAS  Google Scholar 

  5. Smolen JS, Van Der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Schiff M, Baker D, Han C, Han J, Bala M, Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group (2006) Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 54(3):702–710

    Article  PubMed  CAS  Google Scholar 

  6. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T, CHARISMA Study Group (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54(9):2817–2829

    Article  PubMed  CAS  Google Scholar 

  7. Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11(2):97–107

    Article  PubMed  CAS  Google Scholar 

  8. Beasley RP (1988) Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 61(10):1942–1956

    Article  PubMed  CAS  Google Scholar 

  9. Wendling D, Di Martino V, Prati C, Toussirot E, Herbein G (2009) Spondyloarthropathy and chronic B hepatitis: effect of anti-TNF therapy. Joint Bone Spine 76(3):308–311

    Article  PubMed  CAS  Google Scholar 

  10. Domm S, Cinatl J, Mrowietz U (2008) The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 159(6):1217–1228

    Article  PubMed  CAS  Google Scholar 

  11. Weaver AL (2003) Differentiating the new rheumatoid arthritis biologic therapies. J Clin Rheumatol 9:99–114

    Article  PubMed  Google Scholar 

  12. Calabrese LH, Zein N, Vassilopoulos D (2004) Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 63(Suppl 2):18–24

    Google Scholar 

  13. Marinos G, Naoumov NV, Rossol S, Torre F, Wong PY, Gallati H, Portmann B, Williams R (1995) Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology 108(5):1453–1463

    Article  PubMed  CAS  Google Scholar 

  14. Janssen HL, Higuchi H, Abdulkarim A, Gores GJ (2003) Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression. J Hepatol 39(3):414–420

    Article  PubMed  CAS  Google Scholar 

  15. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV (1996) Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4(1):25–36

    Article  PubMed  CAS  Google Scholar 

  16. Carroll MB, Bond MI (2008) Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 38(3):208–217

    Article  PubMed  CAS  Google Scholar 

  17. Michel M, Duvoux C, Hezode C, Cherqui D (2003) Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still’s disease. J Rheumatol 30(7):1624–1625

    PubMed  Google Scholar 

  18. Montiel PM, Solis JA, Chirinos JA, a Casis B, Sánchez F, Rodríguez S (2008) Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 28(5):718–720

    Article  PubMed  Google Scholar 

  19. Ueno Y, Tanaka S, Shimamoto M, Miyanaka Y, Hiyama T, Ito M, Kitadai Y, Yoshihara M, Sumii M, Chayama K (2005) Infliximab therapy for Crohn’s disease in a patient with chronic hepatitis B. Dig Dis Sci 50(1):163–166

    Article  PubMed  Google Scholar 

  20. Miyasaka Nobuyuki, Takeuchi Tsutomu, Eguchi Katsumi (2005) Official Japanese guidelines for the use of infliximab for rheumatoid arthritis. Mod Rheumatol 15:4–8

    Article  PubMed  CAS  Google Scholar 

  21. Koike Ryuji, Harigai Masayoshi, Atsumi Tatsuya, Amano Koichi, Kawai Shinichi, Saito Kazuyoshi, Saito Tomoyuki, Yamamura Masahiro, Matsubara Tsukasa, Miyasaka Nobuyuki (2009) Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 19:351–357

    Article  PubMed  CAS  Google Scholar 

  22. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L (2006) Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 45(10):1294–1297

    Article  CAS  Google Scholar 

  23. Benucci M, Manfredi M, Mecocci L (2008) Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B. J Clin Rheumatol 14(4):245–246

    Article  PubMed  Google Scholar 

  24. Li S, Kaur PP, Chan V, Berney S (2009) Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol 28(7):787–791

    Article  PubMed  CAS  Google Scholar 

  25. Kaur PP, Chan VC, Berney SN (2008) Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports. Clin Rheumatol 27(8):1069–1071

    Article  PubMed  Google Scholar 

  26. Cansu DU, Kalifoglu T, Korkmaz C (2008) Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 35(3):421–424

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest statement

None of the authors have any conflicts of interest in connection with this work.

Author information

Authors and Affiliations

  1. Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Cyuuou-Ku, Niigata, 951-8510, Japan

    Takeshi Kuroda, Yoko Wada, Daisuke Kobayashi, Hiroe Sato, Syuichi Murakami & Ichiei Narita

  2. Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata University, 2-746 Asahimachi-Dori, Niigata, 951-8518, Japan

    Masaaki Nakano

Authors
  1. Takeshi Kuroda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoko Wada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daisuke Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroe Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Syuichi Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masaaki Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ichiei Narita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takeshi Kuroda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kuroda, T., Wada, Y., Kobayashi, D. et al. Effect of etanercept and entecavil in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature. Rheumatol Int 32, 1059–1063 (2012). https://doi.org/10.1007/s00296-009-1344-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-009-1344-2

Keywords

Search

Navigation